Two Kansas cats have contracted bird flu. What vets say about keeping your pets safe
After two cats in Pottawatomie County, Kansas were found to have contracted bird flu, some veterinarians are advising clients to make sure their pets stay safe if the virus continues to spread in the area.
The Pottawatomie County Health Department notified local veterinary offices on March 6 that the two infected felines tested positive for bird flu, according to the Timber Creek Veterinary Hospital in Manhattan, Kansas.
TVHC hasn't seen any cats with bird flu on site, veterinarian Dr. Kellie Lewis told The Star, and staff aren't yet raising the alarm about a potential rise in feline cases.
'It would be new for our area,' Lewis said. 'We have not seen any ill cats in the hospital.'
However, Lewis said, concerned pet parents can take steps to protect their cats, birds and other pets by keeping them indoors and sticking to a diet of commercially available wet and dry food.
'People can keep their outdoor cats inside to limit the exposure that they have to wild birds,' Lewis said. 'I would also recommend feeding a commercial diet instead of a raw food diet and undercooked meat — and stay away from unpasteurized milk, because the virus can be spread through these food sources as well.'
Owners of indoor birds should keep their feathery friends away from open windows and screens, Lewis said, and backyard chickens should be secured in a coop with a strong perimeter.
Though not a major concern in the Kansas and Missouri area as of now, bird flu can kill cats quickly if they do contract it, TVHC shared online. Symptoms start with lethargy, loss of appetite and fever. They can progress to difficulty breathing, discharge from the nose and eyes, and neurological symptoms like seizures and blindness.
Bird flu — officially known as Highly Pathogenic Avian Influenza, HPAI or H5N1 — has been seen nationwide in poultry and wild birds since 2022, but spread to cattle in Kansas and Texas in 2024, according to the U.S. Department of Agriculture. In August 2024, a Missouri man became the 15th person in America to contract the current strain of bird flu. He made a full recovery.
Flu vaccines received for the 2024-2025 flu season may also be partially effective against bird flu in people, Lewis said, since H5N1 is related to Influenza A.
Recent human cases of bird flu have largely impacted those who work closely with poultry and cattle, according to the Centers for Disease Control. The CDC has also not identified cats as a notable source of viral spread as of March. However, the CDC reported online that it is continuing to monitor the spread of bird flu through targeted surveillance and contact tracing.
The bird flu outbreak has also inflated egg prices nationwide, including in the Kansas City area, where some grocery stores have been unable to offer their usual full selection of eggs.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
ACIP Recommends Use of Merck's ENFLONSIA™ (clesrovimab-cfor) for Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants Younger than 8 Months of Age Born During or Entering Their First RSV Season
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) voted to recommend ENFLONSIA™ (clesrovimab-cfor) as an option for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants younger than 8 months of age who are born during or entering their first RSV season. The ACIP also voted to include ENFLONSIA in the Vaccines for Children Program—an important step in ensuring broad access to this preventive option for infants. ENFLONSIA is a preventive, long-acting monoclonal antibody (mAb) designed to provide direct, rapid and durable protection through 5 months, a typical RSV season, with the same dose regardless of weight. A typical RSV season usually spans autumn to spring of the next year. ENFLONSIA should not be administered to infants with a history of serious hypersensitivity reactions, including anaphylaxis, to any component of ENFLONSIA. See additional Selected Safety Information below. 'Ahead of the 2025-2026 RSV season, we are proud to offer ENFLONSIA as a new preventive option designed to protect healthy and at-risk infants from RSV disease across a spectrum of severity, including worsening disease requiring hospitalization,' said Dr. Richard M. Haupt, vice president, head of global medical & scientific affairs, vaccines and infectious diseases, Merck Research Laboratories. 'The Committee's recommendation is an important step forward in efforts to help reduce the significant burden RSV continues to place on infants, families and health care systems.' The U.S. Food and Drug Administration (FDA) approved ENFLONSIA earlier this month based on clinical data from the Phase 2b/3 CLEVER and Phase 3 SMART trials. Merck plans to make ENFLONSIA available for ordering by physicians and health care administrators in July 2025, with shipments to be delivered before the start of the 2025-2026 RSV season. The ACIP's recommendation for ENFLONSIA is provisional and will be official once reviewed and finalized by the CDC Director or the Health and Human Services Secretary (in the absence of a CDC Director). About ENFLONSIA™ (clesrovimab-cfor) ENFLONSIA is Merck's extended half-life monoclonal antibody (mAb) indicated for passive immunization for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants who are born during or entering their first RSV season. ENFLONSIA is administered using the same dose regardless of weight (105 mg/0.7 mL in a prefilled syringe) and is designed to provide direct, rapid and durable protection through 5 months, a typical RSV season. For infants born during the RSV season, ENFLONSIA is to be administered within the first week of life. For infants born outside of the RSV season, ENFLONSIA should be administered shortly before the RSV season begins. For infants undergoing cardiac surgery with cardiopulmonary bypass during or entering their first RSV season, an additional 105 mg dose is recommended as soon as the infant is stable after surgery. ENFLONSIA has a 30-month shelf life. Selected Safety Information for ENFLONSIA™ (clesrovimab-cfor) Do not administer ENFLONSIA to infants with a history of serious hypersensitivity reactions, including anaphylaxis, to any component of ENFLONSIA. Serious hypersensitivity reactions, including anaphylaxis, have been observed with other human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs or symptoms of a clinically significant hypersensitivity reaction or anaphylaxis occur, initiate appropriate medications and/or supportive therapy. The most common adverse reactions were injection-site erythema (3.8%), injection-site swelling (2.7%) and rash (2.3%). About RSV Respiratory syncytial virus (RSV) is a contagious virus that causes widespread seasonal infections and can lead to serious respiratory conditions such as bronchiolitis and pneumonia. According to the CDC, two to three out of every 100 infants under 6 months of age are hospitalized with RSV annually. As the leading cause of hospitalization among infants in the U.S., there is persisting unmet need for RSV preventive options for both healthy and high-risk infants born during or entering their first RSV season. RSV season is the time of year when RSV infections are most common, usually occurring fall/autumn through spring of the next year. RSV typically peaks in the winter in most regions of the United States, but timing and severity in a given community or region can vary year to year. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site ( Please see Prescribing Information for ENFLONSIA (clesrovimab-cfor) at and Patient Information/Medication Guide for ENFLONSIA at
Yahoo
2 hours ago
- Yahoo
RFK Jr.'s vaccine panel votes no on thimerosal. What is that and why is there controversy?
A key vaccine committee, newly appointed by Health and Human Services Secretary Robert F. Kennedy Jr., voted against recommending certain vaccines that contain a preservative long targeted by anti-vaccine advocates despite broad scientific consensus on its safety. The call against the preservative, called thimerasol, was first presented by Lyn Redwood, former leader of Children's Health Defense, an anti-vaccine group founded by Kennedy, during a June 26 meeting for the Advisory Committee on Immunization Practices. She argued that thimerosal is a neurotoxin and the panel should recommend only thimerosal-free flu vaccines for all pregnant women, infants and children. The panel also voted the same recommendation for adults. Health experts were shocked to see that thimerosal, a preservative that has largely been phased out of U.S. vaccines, was on the ACIP agenda when it was posted on the Centers for Disease Control and Prevention website June 25. Before the vote, panel members argued back and forth on whether thimerosal is safe, despite scientific literature showing no link between vaccines containing the preservative and autism or other neurodevelopmental disorders. The eight new ACIP members met for the first time June 25. Kennedy fired all 17 original members of the committee on June 9 and appointed its new members, which included some vaccine skeptics, a few days later. Preservatives, such as thimerosal, are compounds that kill or prevent the growth of microorganisms, such as bacteria and fungi, according to the FDA. However, improvements in manufacturing technology have decreased the need to add such preservatives. A CDC briefing document compiled by staff and posted on its website noted that in the 2024-2025 season, 96% of all influenza vaccines in the U.S. were thimerosal-free. The agency says it has actively addressed the issue of thimerosal as a preservative and its use has significantly declined over the decades. All vaccines routinely recommended for children 6 and under are available in versions that don't contain thimerosal, the FDA said. While most vaccines don't contain thimerosal, the agency states that 'a robust body of peer-reviewed, scientific studies conducted in the United States and countries around the world support the safety of thimerosal-containing vaccines.' 'The scientific evidence collected over the past 20+ years does not show any evidence of harm, including serious neurodevelopmental disorders, from use of thimerosal in vaccines,' the FDA says on its website. Contributing: Julie Steenhuysen and Michael Erman, Reuters Adrianna Rodriguez can be reached at adrodriguez@ This article originally appeared on USA TODAY: RFK, Jr. ACIP panel votes on vaccines with thimerosal: What is that?
Washington Post
2 hours ago
- Washington Post
The woman who could impede RFK Jr.'s anti-vaccine agenda
Susan Monarez might end up being one of the most important people in President Donald Trump's administration. As acting director of the Centers for Disease Control and Prevention and the nominee to hold the position permanently, she has the power to frustrate the anti-vaccine agenda of Health and Human Services Secretary Robert F. Kennedy Jr. Based on her performance at her confirmation hearing on Wednesday, she might just be up to that task. Monarez was nominated after senators balked at the anti-vaccine positions of Dave Weldon, Trump's first choice for the job. She would be the first person without a medical degree to fill the role, but she is a well-respected scientist with a doctorate in microbiology and immunology. She also served as deputy director of the Advanced Research Projects Agency for Health. Most important, she has no record suggesting she subscribes to the vaccine skepticism that Kennedy and many of his newly appointed allies at the CDC have expressed. 'I think vaccines save lives,' she said at her confirmation hearing. She also defended mRNA vaccines, the technology that was used to quickly develop shots against the coronavirus, as 'safe' and insisted she has 'no a priori prejudices against mRNA platform or any other approach that is being taken to develop vaccines.' Monarez spent much of the hearing artfully dodging difficult questions about Kennedy's actions. Regarding his decision to fire everyone on the CDC's Advisory Committee on Immunization Practices and replace them with his own hand-selected advisers, many of whom have criticized vaccines, she offered a cagey response: 'I agree that the secretary had to make a decision related to ensuring that the ACIP could be supportive of restoring public trust in decision-making.' She also said the committee has 'a very vital role to play, and it must make sure that it is using science and evidence to drive that decision-making.' And she insisted its members must go through the proper ethics approval process before participating in meetings. That's probably the best response the public could hope for from a Trump nominee. She deftly managed not to contradict Kennedy's decisions but also avoided strongly endorsing them. She sent an important signal: She could be a real impediment to those seeking to upend vaccine policies that have saved countless lives. No recommendation from ACIP can become government policy without sign-off from the CDC director. If, for example, the committee reviews the childhood vaccine schedule or long-standing immunizations — as its new chair announced it would do on Wednesday — and determines that children shouldn't be receiving certain vaccines at certain times, despite all the evidence to the contrary, Monarez could reject that finding. She could also use her position to press for trusted voices to serve on the committee and push back against false information about vaccines. Of course, there is no guarantee that Monarez would do all this. Trump appointees, including Kennedy, have a history of saying reassuring things about vaccines during their confirmation hearings, only to change course when in office. Nevertheless, the public would be better-off with a serious person such as Monarez at the CDC's helm. The Senate should confirm her, and fast. Monarez, meanwhile, needs to recognize the burden she is accepting. Being CDC director is not an easy job, even in less contentious times. Having to report to Kennedy makes it incalculably harder. Lives will depend on whether Monarez resists Kennedy's efforts to make America sick again. If she's not willing to do that, she should step aside.
